In contrast to the oncogenic role of ALOX5 reported previously in CML26, here we show that ALOX5, suppressed by PRC2 at the transcription level, exhibits a moderate anti-tumor effect both in vitro and in vivo in MLL-rearranged AML, in which ALOX5 expression is especially repressed. The gene discussed is KMT2A; the disease is neoplasm.